Skip to main content

Table 4 Factors obtained from a cox model and associated with observed mortality for adenocarcinomas, squamous cell cancers and small cell cancers diagnosed in 2004 and recruited among 10 French cancer registries

From: Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries

  Adenocarcinomas (n = 646) Squamous cell cancers (n = 524) Small cell cancers (n = 233)
Time (years)a Unadjusted Hazard Ratios Time (years) a Adjusted Hazard Ratios Time (years) a Unadjusted Hazard Ratios Time (years) a Adjusted Hazard Ratios Time (years) a Unadjusted Hazard Ratios Time (years) a Adjusted Hazard Ratios
Sex
 Male   1   1   1   1   1   1
 Female 0–8 0.8 (0.6–0.9) 0–8 0.7 (0.6–0.8) 0–8 1.1 (0.8–1.6) 0–8 1.3 (1.0–1.8) 0–8 0.8 (0.6–1.1) 0–8 0.7 (0.5–1.0)
Age group             
 < 50   1   1   1   1   1   1
 50–59 0–8 1.1 (0.9–1.5) 0–8 1.0 (0.7–1.3) 0–8 1.0 (0.6–1.6) 0–8 0.9 (0.6–1.5) 0–8 1.0 (0.6–1.8) 0–8 0.9 (0.5–1.6)
 60–69 0–8 1.3 (1.0–1.7) 0–8 1.1 (0.8–1.4) 0–8 0.9 (0.5–1.4) 0–8 0.9 (0.5–1.5) 0–8 1.4 (0.8–2.4) 0–8 1.0 (0.6–1.7)
 70–79 0–8 1.2 (0.9–1.6) 0–8 1.2 (0.9–1.6) 0–8 1.1 (0.7–1.8) 0–8 1.4 (0.8–2.3) 0–8 1.9 (1.1–3.2) 0–8 1.3 (0.8–2.3)
 ≥ 80 0–8 2.2 (1.5–3.2) 0–8 2.9 (2.0–4.3) 0–8 1.9 (1.1–3.2) 0–8 1.9 (1.1–3.2) 0–8 3.1 (1.6–6.1) 0–8 2.5 (1.3–4.9)
Charlson Comorbidity Index
 0   1   1   1   1   1   1
 1 0–8 1.0 (0.8–1.2) 0–8 1.0 (0.8–1.3) 0–8 1.0 (0.8–1.3) 0–8 1.0 (0.8–1.3) 0–8 1.3 (0.9–1.8) 0–8 1.6 (1.1–2.3)
 2 0–8 0.9 (0.7–1.2) 0–8 0.8 (0.6–1.1) 0–8 0.9 (0.7–1.2) 0–8 0.9 (0.6–1.2) 0–8 1.4 (0.9–2.1) 0–8 1.7 (1.1–2.7)
 ≥ 3 0–8 1.3 (1.0–1.7) 0–8 1.2 (0.9–1.6) 0–8 1.1 (0.8–1.4) 0–8 0.9 (0.6–1.2) 0–8 2.4 (1.5–3.7) 0–8 2.7 (1.7–4.4)
 Unknown 0–8 2.1 (1.4–3.3) 0–8 1.6 (1.0–2.6) 0–8 1.1 (0.7–1.9) 0–8 0.9 (0.6–1.6) 0–8 1.4 (0.7–2.8) 0–8 1.2 (0.6–2.5)
Stage (non-small cell cancers)
 1   1   1   1   1   
 2 0–8 1.1 (0.6–2.2) 0–1 0.4 (0.1–3.3) 0–8 1.1 (0.7–1.7) 0–8 1.1 (0.7–1.8)   
  1–8 1.3 (0.0–90.3)         
 3 0–8 3.2 (2.2–4.5) 0–1 3.3 (1.6–6.7) 0–8 2.6 (1.8–3.7) 0–8 2.8 (2.0–4.0)   
  1–8 3.3 (0.7–15.3)         
 4 0–8 6.9 (5.0–9.6) 0–1 8.7 (4.4–17.1) 0–8 6.1 (4.3–8.7) 0–8 6.7 (4.6–9.6)   
  1–8 6.4 (1.5–27.5)         
 Unknown 0–8 5.6 (3.0–10.5) 0–1 8.2 (3.2–21.0) 0–8 7.0 (4.3–11.4) 0–8 7.2 (4.4–11.7)   
  1–8 3.2 (0.3–33.2)         
Stage (small cell cancers)
 Limited       1   1
 Extensive      0–8 2.7 (1.9–3.6) 0–8 3.1 (2.2–4.4)
 Unknown      0–8 6.2 (3.1–12.5) 0–8 4.7 (2.1–10.2)
Diagnostic mode
 Pulmonary symptoms   1   1   1   1   1   1
 Incidental diagnosis 0–1 0.8 (0.6–1.0) 0–1 0.7 (0.5–1.1) 0–8 0.9 (0.7–1.3) 0–8 0.9 (0.7–1.2) 0–8 0.7 (0.4–1.1) 0–8 0.8 (0.4–1.3)
1–8 0.7 (0.4–1.3) 1–8 1.0 (0.4–2.5)         
 Non-pulmonary symptoms 0–1 1.3 (1.1–1.6) 0–1 1.1 (0.8–1.4) 0–8 1.8 (1.4–2.3) 0–8 1.5 (1.2–1.9) 0–8 1.2 (0.9–1.7) 0–8 1.1 (0.8–1.5)
1–8 1.6 (0.9–2.6) 1–8 0.9 (0.5–1.7)         
 Surveillance of high-risk patients 0–1 0.5 (0.3–0.7) 0–1 0.4 (0.2–1.1) 0–8 1.0 (0.6–1.8) 0–8 1.1 (0.6–2.0) 0–8 1.0 (0.2–4.1) 0–8 2.0 (0.5–8.7)
1–8 0.3 (0.1–0.8) 1–8 1.2 (0.1–10.4)         
 Unknown 0–1 1.4 (0.8–2.5) 0–1 1.0 (0.5–2.4) 0–8 1.3 (0.6–2.5) 0–8 1.6 (0.8–3.2) 0–8 2.3 (1.0–5.3) 0–8 1.6 (0.6–4.3)
1–8 3.4 (0.8–13.7) 1–8 1.9 (0.3–14.2)         
  1. aPeriod of time since diagnosis considered to compute hazard ratios